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CHAPTER I
INTRODUCTION
Research Problem
Diabetes mellitus affects 15.7 million people in the United States.. with 2,200 new
cases diagnosed each day. Diabetes is the seventh leading cause of death in the United
States'l and as of today there is no cure (American Diabetes Association 2001).
There are two types of diabetes. Type 1 diabetes is a condition where the body no
longer makes insulin. People with Type 1 diabetes must take regular insulin to survive.
Type 1 diabetes is usually diagnosed in children or young adults. Type 2 diabetes is a
condition where the body is not producing sufficient insulin or the body is not using the
insulin it produces effectively. Type 2 diabetes is generally diagnosed in adulthood, and
accounts for 90-950/0 of the diabetes cases in the United States (American Diabetes
Association'l 200 1).
The American Diabetes Association has outlined several risk factors for Type 2
diabetes. People who are at the highest risk for developing Type 2 diabetes are people
over the age of 45 who are overweight, have a family history of diabetes lead sedentary
lifestyles, and have high triglycerides and low HDL cholesterol levels. Some ethnic
groups are also at higher risk for developing Type 2 diabetes such as Native Americans,
African Americans, and Latinos.
Many complications can result from undiagnosed or uncontrolled diabetes such
as blindness, kidney disease and nerve disease. These complications arise due to damage
to the small blood vessels. Heart disease and stroke are complications that can arise due
to long-term damage to the large blood vessels (American Diabetes Association, 200 1).
The health care costs for diabetes~ along with the indirect costs of diabetes such as
lost wages, are approximately $98 billion a year (American Diabetes Association, 2001).
This dollar figure makes research to lower the incidence of diabetes worthwhile.
Glucose intolerance is a condition of impaired glucose levels that may precede
Type 2 diabetes. Chromium., an essential mineral required for normal blood glucose
regulation~ has been shown to improve glucose tolerance in people with Type 2 diabetes
(Mahdi et aI., 1991). Although its role in glucose tolerance is controversial, chromium
supplementation has been shown to increase insulin efficiency by increasing the number
of and/or the effectiveness of insulin receptor sites, and increasing insulin binding
(Anderson, 1992). Increased insulin sensitivity could result in improved glucose
tolerance, which may help avoid or delay the onset of Type 2 diabetes.
Purpose
Since past chromium research has included either healthy people or people
already diagnosed with diabetes, the current study targeted people with glucose
intolerance. If glucose intolerance can be treated successfully, Type 2 diabetes onset may
be delayed or avoided in people who first experience glucose intolerance. The purpose of
this study was to examine the effects of 24 weeks of chromium supplementation with 200
J.!g chromium per day as chromium chloride on three-hour glucose and insulin curves,
glycosylated hemoglobin, and percent specific insulin binding following a 75g oral
glucose load in glucose intolerant men.
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Null Hypotheses
The following are the null hypotheses for this stud :
1. There will be no statistically significant effect of 24 weeks supplementation
with 200 ~g chromium per day, as chromium chloride, on 3-hour serum
glucose curves following a 75 g oral glucose load among glucose intolerant
men.
2. There will be no statistically significant effect of 24 weeks supplementation
with 200 Jlg chromium per day, as chromium chloride., on 3 hour serum
insulin curves following a 75 g oral glucose load among glucose intolerant
men.
3. There will be no statistically significant effect of 24 weeks supplementation
with 200 J.lg chromium per day, as chromium chloride, on glycosylated
hemoglobin concentration among glucose intolerant men.
4. There will be no statistically significant effect of 24 weeks supplementation
with 200 Jlg chromium per day, as chromium chloride on percent specific
insulin binding among glucose intolerant men.
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Assumptions
The following assumptions were made for this research:
1. Participants did not alter their exercise and eating habits during the course of
the study.
2. Participants took one supplement daily for 24 weeks.
3. Participants fasted for twelve hours prior to each blood collection.
4. Participants did not take any other nutritional supplement that contained
chromium during the course of the study.
Limitations
1. The one week food frequency was limited by the participants' knowledge and
understanding of food composition and portion sizes.
2. The dietary analysis was limited due to an inadequate database for chron1ium.
3. The results of this study are limited by outside factors affecting participants
such as illness, change in medication and surgery.
4. The results of this study are limited by the tendency of health conscious
individuals to volunteer for this type of research.
5. The results of the study are representative of this sample, and therefore cannot
be applied to the general population.
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6. A crossover design" which would have provided a larger number of
supplemented individuals, could not be done due to the length of the study for
that design and the possible problems with compliance.
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CHAPTER II
REVIEW OF LITERATURE
Diabetes mellitus
Diabetes mellitus is a disease that affects millions of people in the United States.
In 2001~ it was estimated that 15.7 million people in the United States had diabetes with
only 10.3 million of those cases being diagnosed (American Diabetes Association 200 1).
Type 2 diabetes is the most prevalent form of diabetes, and accounts for 90 to 95% of all
cases. Type 2 diabetes previously known as adult onset diabetes occurs when the body
is not producing sufficient insulin, or when the body is not using the insulin it produces
effectively (American Diabetes Association, 200 1).
There are several risk factors for the development of Type 2 diabetes. People who
are overweight., over the age of 45 and who have a family history of diabetes have a
higher risk of developing Type 2 diabetes. Obesity is one of the biggest risk factors for
the development of Type 2 diabetes (Everhart et aI, 1992). The incidence of Type 2
diabetes drops as BMI (body mass index) decreases and it is suggested that people with
Type 2 diabetes try to reduce their BMI to between 20 and 25 (American Diabetes
Association 200 1). Weight loss in individuals with Type 2 diabetes has been shown to
improve insulin sensitivity and insulin binding to its receptor sites (Pi-Sunyer, 1996). For
individuals who are overweight, the American Diabetes Association recommends weight
loss, even 10 or 20 pounds, as one way to keep Type 2 diabetes under control or to
possibly prevent the onset of Type 2 diabetes (American Diabetes Association, 200 1).
Age is also be a factor in the development of Type 2 diabetes. As people age there is a
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tendency for increased adiposity and increased central obesity (Pi-Sunyer 1996). This
increase in body fat increases the risk for developing Type 2 diabetes. As a reflection of
these risk factors., the incidence of Type 2 diabetes is increasing in the aging population,
as well as among people who are obese and sedentary for all ages (American Diabetes
Association, 200 1).
Type 2 diabetes can lead to many health complications., especially if left
uncontrolled. Complications resulting from uncontrolled diabetes include damage to the
small blood vessels, which can cause blindness, kidney disease nerve damage,
amputations, and impotence in men (American Diabetes Association, 200 I).
Uncontrolled diabetes can also increase the risk of cardiovascular disease and stroke due
to large blood vessel damage (American Diabetes Association 2001).
Many times, these complications can lead to costly hospital stays and other
expensive treatment that could possibly be avoided. In 1997, the health care cost for
diabetes was estimated at $98 billion (Centers for Disease Control, 1999). This figure
includes both direct costs such as inpatient care, which accounts for $44 billion, and
indirect costs, such as lost productivity, premature death, and disability, which account
for $54 billion (Centers for Disease Control, 1999). Some of these costs could be
decreased if the onset of diabetes could be delayed or completely avoided.
Type 2 diabetes can be diagnosed in three ways, according to the Expert
Committee on the Diagnosis and Classification of Diabetes Mellitus (The Expert
Committee on the Diagnosis and Classification of Diabetes Mellitus, 2000). First, an
individual may be diagnosed with diabetes ifhe or she has some symptoms of diabetes,
as well as a plasma glucose concentration of greater than or equal to 200 mg/dl. In this
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case, the plasma glucose concentration is measured at any time of day with no
consideration given as to the time the last meal or snack was consumed. It is important to
note that symptoms of diabetes must also exist in addition to this plasma glucose
concentration.. such as polydipsia and polyuria. Diabetes may also be diagnosed if an
individual has a fasting plasma glucose concentration of greater than or equal to 126
mg/dl. Fasting, in this case, refers to no caloric intake for at least 8 hours prior to the
testing. Finally, the third option for the diagnosis of diabetes is a 2-hour plasma glucose
concentration of greater than or equal to 200 mg/dl following an oral glucose tolerance
test. The committee recommends following the World Health Organization (WHO)
guidelines for the oral glucose tolerance test which include the use of 75g anhydrous
glucose dissolved in water (The Expert Committee on the Diagnosis and Classification of
Diabetes Mellitus, 2000).
Glucose intolerance often precedes the development of Type 2 diabetes. Glucose
intolerance is a condition in which fasting glucose is less than 126 mg/dl., which is
considered normal, but plasma glucose concentration 2 hours after an oral glucose
challenge is between 140 mg/dl and 200 mg/dl, which is considered to be elevated
(American Diabetes Association" 1997). Some studies have reported supplemental
chromium improves glucose concentrations among individuals who have diabetes
(Wallach, 1985). If adequate chromium intake can improve glucose concentrations in
glucose intolerant individuals, Type 2 diabetes onset could possibly be avoided or
delayed (Anderson, 1992).
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Chromium
Chromium which is a ~"white hard, brittle metal of the first transition series can
exist in many states. The most common oxidation states in which chromium exists are 0
+2 +3., and +6 (Borel and Anderson 1984). Of these states, the most stable of these is the
trivalent state (Stoecker, 1990).
Vauquelin first discovered chromium in 1797 (Baruthio., 1992). It was originally
used in industry for several purposes., such as leather tanning and for pigmentation
(Baruthio, 1992). Schwarz and Mertz discovered chromium's biological functions in
1957, and suggested the essentiality of chromium in the human diet. This breakthrough
introduced chromium to the health care world (Schwarz and Mertz, 1959).
Chromium itself acts to "potentiate the action of insulin' in the body (Borel and
Anderson., 1984). In 1957, Schwarz and Mertz observed impaired glucose tolerance in
rats \vas improved due to a substance in brewer's yeast. This substance was found to be
trivalent clrromium (Schwarz and Mertz 1959). For many years, this action was known
as the glucose tolerance factor, or GTF.
Chromium deficiency symptoms can include fasting hyperglycemia, impaired
glucose tolerance, elevated serum cholesterol and triglycerides, decreased insulin
binding, and decreased insulin receptor number. These symptoms have been shown to
improve in many studies with chromium supplementation (Anderson, 1993).
Deficiency of trivalent chromium has been noted and studied, however, toxic
effects are mainly limited to the hexavalent compounds. The human body absorbs these
compounds easily in both the lungs and the digestive tract (Baruthio~ 1992). Toxicity
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symptoms can include ulceration, pain and itching of the skin, ulceration of the nasal
septum .. discoloration of the teeth" and certain types of cancer (Baruthio 1992).
Borel and Anderson (1984) reported that dietar chromium intake of normal
individuals often is less than the minimum suggested intake. Even certain diets that are
accepted as well-balanced contain only 5 to 10 Jlg chromium (Cr) per 1,000 calories
(Anderson et aI., 1997). This intake is well under the Adequate Intake recommendations
of 35 Jlg chromium/day for men and 25Jlg chromium/day for women when average
calorie intake is taken into account (Institute of Medicine 200 1). For example a woman
would need to eat a balanced diet that contained between 2'1500 and 5,000 calories per
day to reach this recommendation. In addition" Schroeder et a1. reported the chromium
content of foods decreases with refining and processing (Schroeder, 1971). Many
Americans consume a majority of foods that are refined or processed in some way,
thereby reducing the chromium content.
It is important to note that this study was conducted under the recommendation of
50-200 Jlg chromium per day for adults, which was the estimated safe and adequate daily
dietary intake (ESADDI) for chromium at the time this study was conducted(National
Research Council 1989). The new dietary recommended intake (DRI) for chromium was
released in January of 200 1. The new Adequate Intake (AI) for chromium was set at 25
Jlg chromium per day for women and 35 Ilg chromium per day for men. No upper limit
was set (Institute of Medicine, 200 1).
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Chromium and Glucose Tolerance
Chron1ium has been proven to be essential in both humans and animals (Borel and
Anderson, 1.984). A study by Schwarz and Mertz demonstrated the essentiality of
chromium in rats. In this study rats fed a "stock diet deficient in chromium resulted in
impaired glucose tolerance. When yeast containing chromium was added to the diet the
rats~ glucose concentrations returned to normal (Schwarz and Mertz, 1957). The
essentiality of chromium in humans dates back to a case study by Jeejeebhoy et a1. in
1977. This case study evaluated a patient on long-term total parenteral nutrition (TPN)
who developed symptoms of diabetes including hyperglycemia and unexplained weight
loss. These symptoms v/ere corrected with the addition of chromium to the TPN solution
which had not previously contained chromium (Jeejeebhoy et al.~ 1977). This study and
other studies on long-term TPN patients show the necessity of adding chromium to TPN
solutions as a standard, but TPN patients are not the only people at risk for chromium
deficiency. Due to the low chromium content in the typical American diet and increased
chromium losses due to refining and processing, many people may be at risk for
inadequate chromium intake (Borel and Anderson, 1984).
Conflicting results have been reported regarding the effects of chromium
supplementation on glucose and insulin concentrations. Research representing both sides
of these findings has been conducted on many species including, but not limited to, rats
and humans.
Several studies have reported beneficial effects of chromium supplementation on
blood glucose and/or insulin concentrations. In a study published by Anderson et a1. 180
people with Type 2 diabetes were given either a placebo or one of two different levels of
11
chromium supplementation. The patients who participated in the study had to be between
35 and 65 years of age'! free of disease other than Type 2 diabetes, have a fasting glucose
concentration of7.2-15.5 mmol/l~ have a 2-hour blood glucose concentration of9.4-16.7
mmol/l, and have a HbA 1c level of8.0-12.0%. The 180 participants were randomly
divided into three groups of 60. The first group received a placebo, the second group
received 1.92 Jlmol of chromium twice per day.. and the third group received 9.6 J.lmol of
chromium twice per day. The chromium was given in the [ann of chromium picolinate,
and the participants were encouraged to take the supplements once in the morning and
once in the evening between meals. Medications were held constant during the study and
the participants were encouraged not to deviate from their normal eating and exercise
routines. At baseline and after 2 and 4 months of supplementation, serum glucose and
insulin were measured at fasting and after a 2-hour glucose challenge using 75g glucose.
Subjects who received 19.2 J.lmol chromium per day had significantly lower fasting and 2
hour serum glucose concentrations and fasting and 2 hour serum insulin concentrations at
2 and 4 months compared to placebo. The group receiving 3.85 Jlmol had a significantly
lower fasting and 2 hour insulin concentrations compared to placebo'! but no significant
differences in serum glucose concentrations were observed (Anderson et aI., 1997).
Fox and Sabovic reported a case study of a 28 year-old woman with Type 1
diabetes. The woman's HbA lc value was 11.30/0 when supplementation with chromium
picolinate was initiated. The woman received 600 Jlg chromium per day. The dosage was
200 Jlg chromium as chromium picolinate three times per day with meals. The participant
self-reported improved home glucose concentrations three months after beginning
supplementation, and these reported glucose concentrations ~ appeared to be about 30 to
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60 mg/dllower than corresponding values before she took chromium picolinate (Fox
and Sabovic'l 1998). A repeat HbAlc value after three months supplementation was 7.90/0
which was an improvement of2.4% over the pre-supplementation HbAlc value. No other
changes in her medications or lifestyle could explain her improved glucose control (Fox
and Sabovic, 1998).
A study by Martinez et al. also reported beneficial effects of chromium
supplementation on glucose tolerance. Eighty-five women between the ages of 59 and 82
participated in the study. Prior to the beginning of this study, participants were
interviewed by research assistants to obtain background information on the use of
prescription and non-prescription medications. Participants were randomly assigned to a
chromium supplement or placebo group. The supplement group received 200 J.lg
chromiunl as chromium chloride in a vial of distilled water daily. The placebo group
received a vial of distilled water only. At baseline and 10 weeks after supplementation
plasma glucose was measured fasting and after a 2-hour glucose challenge with 75g
glucose. Participants with plasma glucose concentrations greater than 100 mg/dl 2 hours
after the glucose challerlge at baseline were classified Hat-risk for impaired glucose
tolerance." The term "medicated" was used in this study to refer to participants using
medications on a regular basis. When divided into '''medicated'' and" non-medicated' for
the purposes of the study, the at-risk non-medicated women in the chromium
supplemented group had a significant decrease in 2-hour plasma glucose concentration
compared to baseline. No significant effect on serum insulin concentration was observed
after 10 weeks supplementation (Martinez et aI, 1985).
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Elias et a1. conducted a stud on the effect of chromium supplementation in
diabetic patients. Four females and 2 males with Type 2 diabetes participated in this
study. Participants were supplemented with three heaped tablespoons (about 52 g) of
brewer's yeast a day for two weeks. The yeast contained 0.4 Jlg chromium per gram of
brewer's yeast, which provided approximately 20.8 Jlg chromium per day. Baseline
measurements were conducted on fasting serum glucose and insulin sensitivity using the
artificial beta cell. Following two weeks supplementation, a significant increase in
insulin sensitivity was observed. Although not significant, mean fasting serum glucose
concentrations decreased for the participants (Elias et a1. 1984).
Uusitupa et a1. conducted a placebo controlled, double-blind, crossover
study which involved supplementation with 200 Jlg chromium as chromium chloride. Ten
participants with Type 2 diabetes (six men and four women) who had been treating their
diabetes with diet therapy alone for at least 1 year participated in a 4-week run in period
and two, 6-week supplementation periods. The run in period, which lasted 4 weeks,
included no treatment or intervention. At the beginning and the end of the run-in period,
and after 6 and 12 weeks supplementation participants were tested for mean fasting
blood glucose and serum insulin, I-hour blood glucose and serum insulin, 2-hour blood
glucose and serum insulin, and HbA lc concentrations. During the first 6 weeks of
supplementation, participants received either the placebo or chromium supplement, and
the alternate treatment was given to participants in the final 6 weeks with no washout
period. No significant differences were observed in the participants' mean fasting blood
glucose or serum insulin I-hour blood glucose or serum insulin"! 2-hour blood glucose or
serum insulin, or HbA 1c concentrations when compared to the same values taken at
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baseline. HO\\leVer, mean I-hour blood glucose concentrations tended to be lower during
the chromium supplementation period when compared to the placebo, but the results
were not found to be statistically significant (Uusitupa et aI., 1983).
Whereas some studies have reported beneficial effects of chromium
supplementation on blood glucose or insulin concentrations other studies have not
reported beneficial effects with chromium supplementation. A crossover study by Lee
and Reasner investigated the effect of chromium supplementation in 28 patients with
Type 2 diabetes. Participants were between the ages of 32 and 65, and were comprised of
both men and women who were randomly assigned to one of two groups. The study
involved a supplementation period with either 200 J.lg chromium as chromium picolinate
or a placebo for 2 months, followed by a washout period of 2 months in which no
treatment was used. The washout period was followed by another supplementation period
where the participants received the alternate capsule (chromium or placebo). Fasting
serum glucose and HbA 1c were measured at baseline and every 2 months following until
the study's end. No significant effect was observed in fasting glucose or HbA 1c values
between the placebo or chromium supplementation periods (Lee and Reasner, 1994).
Abraham et a1. also report no significant effect of chromium supplementation on
fasting serum glucose concentrations. Seventy-six patients, the majority of.which were
men, were randomly assigned to either a supplement group receiving 250 IJ.g of
chromium per day as chromium chloride or a placebo group. The participants were 42 to
83 years of age, some were diabetic and some were not. Fasting glucose was measured at
baseline after three months supplementation and at the end of supplementation for each
participant, which ranged from 7 to 16 months. No significant effect was observed in
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fasting glucose concentrations folIo ing chromium supplementation compared to
baseline (Abraham et aI., 1992).
In a study by Wilson and Gond , 26 olunteers participated in a double-blind trial
in which they were randomly assigned to either a chromium supplement group receiving
220 J-lg chromium as chromium (III) nicotinate or placebo group for 90 days. Volunteers
were excluded from the study if they had a history of chronic disease if they had recently
experienced a weight loss or gain greater than 10 pounds, or if they were a competitive
athlete, dancer, or gymnast. Fasting glucose was measured at baseline and within one
week of the end of supplementation. No significant effect was observed in fasting glucose
concentrations after 90 days chromium supplementation (Wilson and Gondy .. 1995).
The inconsistent results observed with chromium supplementation may be due in
part to differences in subjects health or chromium status. Chromium deficiency has been
implicated as a possible cause of diabetes (Rabinowitz et aI, 1983). As a result healthy
individuals with appropriate glucose tolerance and insulin sensitivity, or individuals who
show no signs of marginal chromium deficiency would most likely not benefit from
receiving additional chromium through supplementation (Anderson, 1992).
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CHAPTER III
MATERIALS AND METHODS
Approval and Training
This study was approved by the Oklahoma State Universit Institutional Review
Board for human subjects research (Appendix A). The researchers in the study were Dr.
Janice Hermann, Joshua Phelps and Rachael Condley. The researchers underwent both
laboratory and radioactive materials safety training.
Population
Subjects were solicited by flyers mailed campus-wide and to community
organizations (Appendix B). Flyers were also distributed throughout the community and
advertisements were placed in the Stillwater NewsPress and the Daily O'Collegian,
which is Oklahoma State University s daily newspaper for students., faculty and staff
(Appendix C). Adult males were solicited to screen for the study if they had one or more
risk factors for developing diabetes; family history of diabetes over 40 years of age., or
overweight. Subjects interested in participating were screened for a fasting glucose
concentration of <126 mg/dl and a 2-hour glucose concentration following a glucose load
with 75 g dextrose between 130 and 199 mg/dl. Subjects who met the study criteria and
were willing to participate had to be available to attend all of the data collection periods
and had to be willing to stop taking any nutritional supplements containing chromium
during the length of the study.
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Screening
Subjects interested in screening for the stud were asked to come to the
Oklahoma State University Student Health Center following a 12 hour fast, but were
advised to consume water. The subjects filled out an informed consent for the screening
(Appendix D)~ and a health questionnaire (Appendix E). Height was measured to the
nearest half-inch~ and weight was measured to the nearest half-pound on a digital scale.
Body Mass Index (BMI) was calculated using the equation' body weight (kg)/ height
(m2) (Meisler and St. Jeor~ 1996).
Subjects received a finger stick fasting blood glucose test with a B-Glucose
Photometer (HemoCue AB, Angelholm., Sweden) prior to administering a glucose
challenge to identify anyone who might already be diabetic. Anyone with fasting blood
glucose> 126 mg/dl was counseled by a physician and was not given the glucose
challenge. Subjects ",,-hose finger stick fasting glucose concentration was less than 126
mg/d; had a fasting blood san1ple drawn by a licensed phlebotomist in a 6 ml serum tube
(Franklin Lakes, NJ). Subjects were then given a glucose tolerance beverage Trutol®,
containing 75 g dextrose (Appendix F). A second blood sample was drawn into a 6 ml
vacutainer serum tube (Franklin Lakes, NJ) two hours after consuming the Trutol®.
Following the two-hour blood draw., subjects were given nutritional support that
consisted of a small sandwich, chips., orange juice, and a muffin.
One hundred and twelve potential participants were screened for the current
study, and 22 met the study criteria following the screening. Twenty subjects who met the
study criteria of a fasting blood glucose concentration <126 mg/dl and a two-hour blood
glucose concentration between 130 and 199 mgidl following the glucose challenge
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agreed to participate in the study. The subjects were matched into 2 groups based on their
fasting serum glucose two-hour serum glucose age, and BMI. Matching was done to
ensure that the groups were similar at baseline. Ten participants were placed into each
group. The placebo or chromium supplement was randomly assigned to the groups.
Experimental Design
The research design was a pretest/posttest control group. This study involved two
groups~ a control group receiving a lactose placebo and an experimental group receiving
a supplement containing 200 Jlg chromium as chromium chloride. Subjects were
screened.for eligibility, and those who met the study criteria were matched into 2 groups,
which included a placebo group and a supplement group. The groups were matched based
on age, BMI, fasting serum glucose concentration, and a 2 hour serum glucose
concentration following a 75 g oral glucose load'! which were measured at the screening.
The treatment, placebo or chromium supplement was randomly assigned to the two
groups. Data were collected at baseline and after 24 weeks supplementation. Data were
collected in Stillwater, OK at the Oklahoma State University Student Health Center so
the subjects would be in close proximity to a physician in case of an adverse reaction
during the oral glucose challenge.
Supplements
The placebo and chromium supplements were prepared using a gelatin capsule
filler machine (Quanterron, Inc., Burnsville, MN) in the Nutritional Sciences Laboratory
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at Oklahoma State University. White nuolber t 0 gelatin capsules ere used
(Apothocary Product Inc.., Minneapolis .. MN) so that the placebo and chromium
supplements would appear similar.
Placebo supplements wTere filled with an a erage of O.24g USP grade lactose
(Spectrum Quality Products, Inc. Gardena., CA). Chromium supplements were prepared
by mixing 2.05g USP grade CrCI3-6H20 (Spectrum Quality Products Inc q Gardena.. CA)
with 477.95g USP grade lactose (Spectrum Quality Products, Inc. Gardena.. CA). The
chromium supplement mixture was mixed in a ball mixer (U.S. Stoneware East
Palesting, OH) for 24 hours to disperse the chromium throughout the lactose.
Both the chromium and the placebo supplements were analyzed for chromium
content using atomic absorption spectrophotometer., Model 5100 PC (Perkin-Elmer
Corp., Norwalk, CT). Eight 0.1 g randomly chosen samples from the placebo and
chromium mixtures were wet and dry ashed using a modification of the Hill et a1. method
(Hill et aI., 1986). The average analyzed chromium content of the placebo was -0.484
~g/g. The average analyzed chromium content of the chromium supplement mixture was
658.275 ~g/g. As a result, the fill weight of the chromium supplement was adjusted to
0.3038 g to provide 200 Jlg chromium per supplement.
Data Collection
Baseline Data Collection
Subjects who qualified and agreed to participate in the study were asked to
participate in a baseline data collection process before beginning supplementation.
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Subjects were asked to fast for twelve hours prior to the collection, but were encouraged
to drink water. At the baseline data collection" subjects were asked to sign an informed
consent for the study (Appendix G). Subjects were also instructed on and completed a 1-
week food frequency, a modification of the Willetts food frequency questionnaire (Eck et
aI., 1991 ~ Appendix H). Subjects' weight and height were measured to the nearest half-
pound and half-inch, respectively. A fasting blood sample was drawn by a licensed
phlebotomist in a 10 ml vacutainer serum tube and a 10 ml heprinized tube (Franklin
Lakes, NJ), after which the subjects consumed a glucose drink Trutol®" which contained
75 g dextrose. Subjects had a blood sample drawn in a 6 ml vacutainer serum tube
(Franklin. Lakes, NJ) at 30, 60 120, and 180 minutes after consuming the glucose
tolerance beverage. Following the 180 minute blood draw, subjects were provided with
nutritional support consisting of a sandwich.. chips" muffins and orange juice. Subjects
received $150 for the baseline data collection.
One group of 10 men received the chromium supplement containing 200 Jlg
chromiuffi'l which at the time of the study was at the upper end of the safe and adequate
intake range (Stoecker, reference I need to get), once daily for 24 weeks. The other group
of 10 received a placebo pill containing USP grade lactose only. The subjects received an
individually delivered bottle of supplements each month containing more supplements
than necessary for that month. Researchers counted the leftover pills after each delivery
to establish compliance. Subjects were instructed to take one supplement per day with a
meal.
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Post Data Collection
After 24 weeks of supplementation.. subjects were asked to come to a post-data
collection following a 12-hour fast. At the post data collection, suspects were weighed
and were asked to complete the one-week food frequency questionnaire. A fasting blood
sample was drawn by a licensed phlebotomist in a 10 ml vacutainer serum tube and a 10
ml vacutainer heprinized tube, after which the subjects consumed a glucose tolerance
beverage Trutol®. A 6 ml sample was drawn in a vacutainer serum tube by licensed
phlebotomist 30, 60, 120, and 180 minutes after consulning the glucose tolerance
beverage. Following the 180 minute blood draw, the subjects were provided with
nutritional support. Subjects received $150 for participating in the post data collection.
Blood Handling
The same blood handling procedures were used at both the pre and post
collections. Fasting blood collected in heprin tubes was kept on ice for 30 minutes. A 0.5
ml sample of whole blood was then removed and stored at -20oe in a parafilmed
microcentrifuge tube for future analysis of glycosylated hemoglobin. Erythrocyte
membrane ghosts were then obtained from the remaining heprinized blood using a
methed developed by Dodge et al. (1963). The erythrocyte membranes were then stored
at -70°C for future analys"is of percent specific insulin binding and protein concentration.
Fasting, 30, 60, 120, and 180 minute serum tubes were kept on ice for 30 minutes
and then centrifuged to obtain the serum. Serum was then aliquoted and stored at -20°C
in 0.5 ml parafilmed microcentrifuge tubes for future analysis of serum glucose and
insulin.
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Laboratory Analyses
Glucose
Serum glucose concentrations were analyzed using Roche Kit #47382 (Roche
Diagnostic System, Inc.~ Branchburg Township, Son1erville, NJ) on the COBAS FARA
(COBAS FARA, Roche Diagnostic System, Inc., Montclair, NJ)
Insulin
Serum insulin concentrations were analyzed using OPC kit #2812 (Diagnostics
Products Corporation, Los Angeles, CA) on the Gamma Counter (Packard Instruments
Company, Downers Grove, IL).
Glycosylated Hemoglobin
Fasting whole blood glycosylated hemoglobin was analyzed by Roche kit #47212
(Roche Diagnostics Corporation, Indianapolis~ IN) on the COBAS FARA. (COBAS
FARA, Roche Diagnostic System, Inc., Montclair, NJ)
Percent Specific Insulin Binding
Right-side-out erythrocyte ghosts were prepared from erythrocytes using a
method developed by Dodge et al (1963). The erythrocyte ghosts were used to determine
percent specific insulin binding per 100 J.lg protein using a method developed by
Gambhir and Bhathena (Gambhir et a1. 1977; Bathena et aI., 1989; Bathena et a1.., 1995).
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Protein Concentration of Erythrocyte Ghosts
Protein concentrations of erythrocyte ghost samples ere determined using BI0-
RAD protein assay kit #500-001 (Los Angeles, CA) on the spectrophotometer (Beckman~
Du 640 Spectrophotometer).
Anthropometries
Height was measured to the nearest half-inch using a fixed measurement station
set up at the baseline collection. Weight was calculated at both the pre and post data
collections to the nearest half-pound on a digital scale. BMI (body mass index) was
calculated using the equation body weight (kg)/ height (m2) (Meisler and St. Jeor~ 1996).
Food Frequency Analysis
The one week food frequency questionnaire was used to monitor for changes in
participants dietary intake. The questionnaire was a modification of Willets one year food
frequency (Eck et a1.., 1991). The one week food frequency questionnaires were analyzed
using the Food Processor Plus Program (version 7.11~ ESHA Research~ Salem, OR).
Standardized food codes were used throughout the study. The frequency forms were
analyzed for kilocalories~ protein.. carbohydrates total fat, and fiber.
Data Analysis
Data were analyzed using the Statistical Analysis System (SAS) repeated
measures and least square mean procedures available at Oklahoma State University (SAS
Inst. Inc. Cary, NC., 1999). The significance level for all testing was set at p S 0.05. The
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effect of the independent variable., chromium supplementation, on the dependent
variables 3-hour serum and glucose curves following a 75 g oral glucose tolerance test
glycosylated hemoglobin, and percent specific insulin binding ere determined.
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CHAPTER IV
RESULTS A D DISCUSSIO
Results
Participants
Twenty participants.. lOin the chromium and lOin the placebo group participated
in the study. Three participants were excluded from the final data analysis. One
participant was found to be non-compliant due to missing the last month of supplements
and two p.articipants failed to arrive for the post data collection. As a result nine
participants in the chromium supplementation group and eight in the placebo group were
included in the final data analysis.
Age
No significant difference was observed based on t-test analysis between the mean
age of the participants in the clrromium group and placebo group (TABLE I). The
chromium group had a mean age of 50 ±3 years., while the mean age of the placebo
group was 45 ±4 years.
TABLE I.
Mean age., weight, and body mass index at baseline and after 24 weeks of
supplementation with CrCI3.6H20 or a placebo*
Chromium group (n =: 9) Placebo group (n = 8)
Baseline Posttest Baseline Posttest
Weight (lbs) 248 + 12 243 + 11 237 + 15 23 I ± 17
Body Mass Index (kg/m2) 34 + 2 33 + 2 33 + 2 32 ±2
Age (years) 50 + 3 45 + 4
*Values are mean ±SEM
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Weight
Repeated measures analysis of ariance did not sho a significant group by time
interaction for total body weight (TABLE II). In the chromium group the mean total
body weight was 248 ± 12 pounds at baseline and 243 ± 11 pounds at posttest. The mean
total body weight of the placebo group was 237 ± 15 pounds at baseline and 23 I ± 17
pounds at posttest (TABLE I). Repeated measures analysis of variance did show a
significant group effect, with the chromium group being an average of 11 pounds heavier
than the placebo group at baseline and 12 pounds heavier than the placebo group at
posttest (TABLE II). Although not significant., repeated measures analysis of variance
showed a trend for a significant time effect on weight with baseline weight being higher
than posttest weight for both groups (TABLE II).
TABLE II
Analysis of variance summary table for weight and body mass index after
24 weeks supplementation with CrCI3.6H.,0 or a placebo*
-
Source of Variance Probability
group 0.0010*
Weight
time 0.0509
group*time 0.8783
group 0.0012*
Body Mass Index
time 0.0507
group*time 0.8078
*Significance at p S 0.05
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Body Mass Index
Repeated measures analysis of variance did not show a significant group b time
interaction for body mass index (BMI) (TABLE II). The supplement group had an
average BMI of 34 ± 2 kg/m2 at baseline and 33 ± 2 kg/m2 at posttest. In the placebo
group, the average BMI was 33 ±2 kg/m2 at baseline and 32 ±2 kg/m2 at posttest
(TABLE I). Repeated measures analysis of variance did show a significant supplement
effect (TABLE II). The average BMI of the chromium group was 1 kg/m2 higher than the
average BMI for the placebo group at both baseline and posttest. Although not
significant, repeated measures analysis of variance did show a trend for a significant time
effect on BMI with baseline BMI being higher than posttest 8MI for both groups
(TABLE I).
Dietary Intake
Repeated measures analysis of variance did not show a significant group by time
interaction for dietary intake (TABLE III). Repeated measures analysis of variance did
show a significant time effect for kilocalorie, carbohydrate, and fiber intake (TABLE III).
Mean kilocalorie, carbohydrate, and fiber intakes were higher for both groups at baseline
than at posttest (TABLE IV). At baseline, kilocalorie intake was 2521 ±224 and 2349 ±
329 for the chromium and placebo groups respectively. At posttest kilocalorie intake had
decreased to 2058 ±242 and 1763 ±341 for the chromium and placebo groups
respectively. At baseline, carbohydrate intake was 325 ±34 g and 281 ±34 g for th~
chromium and placebo groups, respectively. At posttest carbohydrate intake decreased to
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243 ± 29 g and 194 ± 33 g for the chromium and placebo groups, respectively. Fiber
intake was 23 ±2 g and 22 ±4 g for the chromium and placebo groups at baseline
respectively, then decreased to 18 ±2 g and 14 ± 3 g for the chromium and placebo
groups at posttest~ respectively (TABLE IV).
Repeated measures analysis of variance also showed a significant group effect for
carbohydrate intake with the chromium group having a significantly higher carbohydrate
intake than the placebo group at both baseline and posttest (TABLE III). The mean
carbohydrate intake for the chromium group was 325 ±34 g and 243 ±29 g at baseline
and posttest respectively (TABLE IV). The placebo group had a mean carbohydrate
intake of 281 ± 34 g at baseline and 194 ±33 g at posttest (TABLE IV).
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TABLE III
Analysis of variance summary table for kilocalorie protein, carbohydrate" fiber.,
and fat intakes after 24 weeks supplementation with CrC13.6H20 or a placebo*
Source of Variance Probability
group 0.1823
Kilocalorie intake
time 0.0068*
group*time 0.7198
group 0.1237
Protein intake
time 0.2295
group*time 0.7464
group 0.0436*
Carbohydrate intake
time 0.0012*
group*time 0.8999
group 0.5489
Fat intake
time 0.0889
group*time 0.8296
group 0.2604
Fiber intake
time 0.0084*
group*time 0.6052
*Significance at p ~ 0.05
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..
Chromium group (n == 9) Placebo group (n == 8)
Baseline Posttest Baseline Posttest
Kilocalorie intake 2521 + 224 2058 + 242 2349 + 329 1763 + 341
Protein intake (g) 100 + 9 93 + 13 90 + 13 77 + 13
Carbohydrate intake (g) 325 + 34 243 + 29 281 + 34 194 + 33
Fat intake (g) 93 + 9 79 + 10 90 + 18 72 + 17
Fiber intake (g) 23 + 2 18 + 2 22 + 4 14 + 3
TABLE IV
Mean kilocalorie protein, carbohydrate., fiber, and fat intakes at baseline
and after 24 weeks supplementation with CrC13.6H 0 or a placebo*
* Values are at mean ± SEM
Serum Glucose
At fasting (0 minutes) repeated measures analysis of variance showed a
significant group effect with the chromium group having a significantly lower fasting
glucose concentration than the placebo group at both baseline and posttest (TABLE V).
The mean serum glucose concentrations at baseline were 116 ± 6 mg/dl and 119 ± 7
mg/dl for the chromium and the placebo groups respectively (TABLE VI). At posttest
n1ean serum glucose concentrations were 117 ±6 mg/dl and 123 ± 5 mg/dl for the
chromium and placebo groups respectively (TABLE VI). Repeated measures analysis of
variance also showed a significant group by time interaction for serum glucose
concentrations 30 and 60 minutes after a 75 g oral glucose tolerance test (OGTT). The
mean serum glucose concentration of the chromium group 30 minutes after a 75 g OGTT
was 201 ± 14 mg/dl at baseline and 178 ± 14 mg/dl at posttest (Ti\BLE VI). The placebo
group had a mean serum glucose concentration of 188 ± 19 mg/dl at baseline and 211 ±
19 mg/dl at pasttest 30 minutes after the OGTT (TABLE VI). For the chromium group at
60 minutes after the OOTT the mean serum glucose was 240 ±23 mg/dl and 214 ± 22
mg/dl, respectively (TABLE VI). At 60 minutes after the OGTT, the placebo group had a
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mean serum glucose concentration of 231 ±28 mg/dl at baseline and 241 ±24mg/dl at
posttest (TABLE VI). Repeated measures analysis of variance also showed a trend,
though not significant, for a group by time interaction for the total area under the glucose
curve (TABLE V). Total area under the glucose curve for the chromium group was 811 ±
56 mg/dl at baseline and 740 ±60 mg/dl at posttest. For the placebo group total area
under the glucose curve was 803 ± 72 mg/dl at baseline and 850 ± 71 lng/dl at posttest
(TABLE VI).
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TABLE V.
Analysis of variance sunlmary table for serunl glucose concentration
Following a 75 g OGTT after 24 weeks supplementation with
CrC13.6H?O or a placebo*
-
Source of Variance Probability
group 0.0305*
ominutes time 0.2051
group*time 0.3698
group 0.3158
30 minutes time 0.9902
group*time 0.0278*
group 0.2360
I
60 minutes time 0.2791
group*time 0.0250*
group 0.2317
120 minutes time 0.8986
group*time 0.6199
group 0.1005
180 minutes time 0.6006
group*time 0.2715
group 0.0931
Total area under glucose time 0.07336
curve
-
group*time 0.0530
* Significance at p ::: 0.05
Values are gIven In mg/dl Values are mean ±SEM
TABLE VI.
Mean serum glucose concentration following a 75 g OGTT at baseline and after
24 weeks of supplementation ith CrCI3.6H20 or a placebo 1.2
Chromium group (n == 9) Placebo group (n = 8)
Baseline Posttest Baseline Posttest
ominutes 116 + 6 117 + 6 119 + 7 123 + 5
30 minutes 201 ± 14 178 + 14 188 + 19 211 + 19
60 minutes 240 ±23 214 + 22 231 + 28 241 + 24
120 minutes 152 + 15 149 + 14 160 + 19 166 + 20
180 minutes 101 + 9 96 + 13 105 + 9 109 -t- 16
Total area 811 ±56 740 ±60 803 ±72 850 + 71
under glucose
curve
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Serum Insulin
Repeated measures analysis of variance did not show a significant group by time
interaction for mean serum insulin concentration in response to a 75 g OGTT (TABLE
VII). There was'l however, a significant group effect for mean serum insulin
concentration with the chromium group having a significantly lower serum glucose
concentration 30 minutes following the OOTT than the placebo group at both baseline
and posttest (TABLE VII). The mean serum insulin concentration for the chromium
group at 30 minutes following the 75 g glucose challenge was 12 JlIU/mllower than the
placebo group at baseline and 32 flIU/mllower than the placobo group at posttest
(TABLE VIII). Repeated measures analysis of variance showed a significant group effect
for the total area under the insulin curve (TABLE VII) with the chromium group having
a significantly lower area under the insulin curve than the placebo group at both baseline
and posttest. The total area under the insulin curve for the chromium group was 359 ±65
JlIU/ml at baseline and 271 ± 47 flIU/ml at posttest, while the total area under the curve
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for the placebo group was 375 ±45 ~IU/ml at baseline and 408 ±69 I1IU/ml at posttest
(TABLE VIII).
TABLE VII.
Analysis of ariance summary table for serum insulin concentration folIo ing a
75 g OGTT after 24 weeks supplementation ith CrC13.6H20 or a placebo*
Source of Variance Probability
group 0.1365
ominutes tin1e 0.4492
group*time 0.3692
group 0.0197*
30 minutes time 0.8071
group*time 0.2375
group 0.1893
60 minutes time 0.0857
group*time 0.0673
group 0.0994
120 minutes time 0.7899
group*time 0.3041
group 0.0799
180 minutes time 0.8220
group*time 0.1437
group 0.0369*
Total area under insulin time 0.5990
I curve
group*time 0.0993
* Significance at p ~ 0.05
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Values are gIven In f.lIU/ml Values are mean ± SEM
TABLE VIII.
Mean serum insulin concentration following a 75 g OOTT at baseline and after
24 k fl' . h C CI 6H 0 I b I 2ee S 0 supp ementatlon WIt r 3· 2 or a pace 0 .
Chromium group (n = 9) Placebo group (n == 8)
Baseline Posttest Baseline Pasttest
ominutes 24 + 4 20 +4 26 + 2 26 + 5
30 minutes 78 ± 14 70 + 12 90 + 16 102 + 29
60 minutes 130 + 23 93 + 16 124 + 17 125 + 27
120 minutes 85 + 22 62 + 8 90 + 19 100 + 26
180 minutes 42 + 13 32 + 12 45+ 13 55 + 26
Total area 359 ± 65 271 + 47 375 ±45 408 ± 69
under insulin
curve
1 2
Glycosylated Hemoglobin
Repeated measures analysis of variance did not show a significant group by time
interaction for mean percent glycosylated hemoglobin (TABLE IX). Repeated measures
analysis of variance did show a significant group effect for mean percent glycosylated
hernoglobin (TABLE IX), with the chromium group having a significantly lower percent
glycosylated hemoglobin at both baseline and posttest compared to the placebo group.
Repeated measures analysis of variance also showed a signitIcant time effect for mean
percent glycolylated hemoglobin with both the chromium and placebo groups having
significantly lower percent glycosylated hemoglobin at baseline compared to posttest. In
the chromium group, the mean percent gIycosylated hemoglobin levels were 5.7 ±0.1 %
at baseline and 5.8 ± 0.1 % at posttest (TABLE X). The mean percent glycosylated
hemoglobin levels for the placebo group were 5.8 ±0.1 o~ at baseline and 6.2 ±0.2 % at
posttest (TABLE X).
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TABLE IX.
Analysis of variance summar table for percent glycos lated hemoglobin and
percent specific insulin binding after 24 eeks supplementation with
CrC13.6H,O or a placebo*~
Source of Variance Probability
group 0.0224*
Glycosylated Hemoglobin time 0.0092*
group*time 0.1329
group 0.4445
Percent Specific Insulin time 0.0579
Binding
(per 100 J.lg protein) group*time 0.6808
* Significance at p :s 0.05
TABLE X.
Mean percent glycosylated hemoglobin and percent specific insulin binding at
b l' d ft;4 k fl· . h C CI 6H 0 I b *ase Ine an a er _ wee S 0 supp ementatlon WIt r 3· 2 or a pace 0
Chromium group (n = 9) Placebo group (n == 8)
Baseline Posttest Baseline Posttest
Glycosylated Hemoglobin 5.7±0.1 5.9±O.1 5.8±0.I 6.2 ± 0.2
(0/0)
Specific Insulin Binding (%) 3.0 + 0.4 2.4 ± 0.2 3.4 ± 0.2 2.6 ±0.1
(per 100 Jlg protein)
* Values are at mean ±SEM
Percent Specific Insulin Binding
For mean percent specific insulin binding, repeated measures analysis of variance
did not show a significant time by group interaction (TABLE IX). There was a trend for a
significant time effect with percent specific insulin binding tending to decrease from
baseline to posttest for both groups (TABLE IX). The mean percent specific insulin
binding per 100 Jlg protein for the supplement group was 3.0 ±0.4 % at baseline, and 2.4
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±0.2 % at posttest (TABLE X). In the placebo group, the percent specific insulin binding
per 100 J.1g protein was 3.4 ± 0.2 % at baseline and 2.6 ± 0.1 % at posttest.
Discussion
Weight and Body Mass Index
o significant tin1e by group interaction as observed in the current study for
weight or body mass index. This was a desired observation., since the participants were
instructed not to change their dietary or exercise habits for the duration of the study.
Dietary Intake
A significant time effect was observed for kilocalorie'\ carbohydrate, and fiber
intake with kilocalories, carbohydrate and fiber intakes significantly decreasing in both
groups from baseline to posttest. This was not a desirable observation because the
participants were instructed not to change their dietary habits for the duration of the
study. The dietary data were., however, self-reported.
Serum Glucose
Ho 1: There will be no statistically significant effect of 24 weeks supplementation
with 200 ~g chromium per day as chromium chloride, on 3-hour glucose curves
following a 75 g oral glucose load among glucose intolerant men.
Although not significant there was a trend in the current study for a group by
time interaction for total area under the glucose curve with the chromium group tending
to have a significant decrease in the total area under the glucose curve from baseline to
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posttest compared to the placebo group. A significant group b time interaction was
obser ed for serum glucose concentration at 30 and 60 minutes following an OGTT with
serum glucose concentration significantly decreasing from baseline to posttest 30 and 60
minutes following an OGTT in the chromium group compared to the placebo. Since
significant results were found, the researchers reject the null hypothesis.
FIGURE I
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These observations are similar to those reported in other studies. A study by
Anderson et al. also reported a significant decrease in serum glucose concentrations·with
chromium supplementation when compared to a placebo. Participants were given 19.2
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J.lffiol chromium as chromium picolinate per da for four months. The participants in this
study were diagnosed \vith type 2 diabetes.. and fasting and 2-hour serum glucose
concentrations were higher at baseline than the fasting and 2-hour serum glucose
concentrations in the current study (Anderson et a1. .. 1997).
In a case study by Fox and Sabovic, a woman with type 1 diabetes self reported a
decrease in blood glucose concentrations after supplementation with 600 Jlg chromium as
chromium picolinate for three months. The level of chromium supplernentation in the
case study reported by Fox and Sabovic was three times the amount given to participants
in the current study (Fox and Sabovic 1998).
A study by Abraham et a1.; however, reported no significant effect of chromium
supplementation on fasting serum glucose concentrations (Abraham et a1.., 1992). In this
study., seventy-six participants (the majority being men; some diabetic and some healthy)
were randomly assigned to either a supplement or placebo group. The supplement group
received 250 J.lg chromium per day as chromium chloride, which was only 50 J.lg more
chromium than the current study. T'he participants were supplemented for 7 to 16 months
(Abraham et aI., 1992).
Serum Insulin
H02: There will be no statistically significant effect of 24 weeks supplementation with
200 J.lg chromium per day, as chromium chloride., on 3 hour insulin curves following a 75
g oral glucose load among glucose intolerant men.
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Repeated measures analysis of ariance did not sho a significant group by time
interaction for an point in the insulin curve therefore the researcher fails to reject the
null hypothesis.
FIGURE II
3-hour mean insulin
concentrations
160
140
120
E 100
:5 80
:i 60
40
20
a
o 30 60
minutes
120 180
placebo baseline 0 placebo posttest
ED chromium baseline 0 chromium posttest
These results are similar to those reported by Martinez et a1. Martinez et a1.
reported no significant effect on serum insulin concentrations as a result of 1qweeks
chromium supplementation (Martinez et a1. 1985). Eighty-five women ages 59 to 82
who were either healthy or who. were considered to be "at risk" for glucose intolerance by
study standards, participated in the research. Participants were randomly assigned to
either a chromium supplement group which received 200 Ilg chromium per day as
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chromium chloride in a vial of water, or a placebo group which received a vial of plain
water (Martinez et al.'\ 1985).
Anderson et a1. did report a significant effect on serum insulin concentration after
2 and 4 months chromium supplementation compared to placebo for participants who
received 3.85 Jlmol chromium per day as chromium picolinate (Anderson et al. 1997).
The participants in this study differed from the participants in the current study in that
they had been diagnosed with type 2 diabetes., and were a mixed group of men and
women with no separation given to pre or post menopausal state (Anderson et al. 1997).
Glycosylated Hemoglobin
Ho3 : There will be no statistically significant effect of 24 weeks supplementation
with 200 Jlg chromium per day, as chromium chloride on glycosylated hemoglobin
concentration among glucose intolerant men.
Repeated measures analysis of variance did not show a significant group by time
interaction for glycosylated hemoglobin, therefore the researcher fails to reject the null
hypothesis. Glycosylated hemoglobin which is used as a long-term indicator of glucose
tolerance is between 40/0 and 8% in individuals without diabetes (Lee and Nieman
2000). Percent glycosylated hemoglobin in the current study fell within the 4% to 8°~
range at both baseline and posttest. Since the observed values were in the nonnal range to
begin with., a change would not be expected as a result of chromium supplementation.
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Percent Specific Insulin Binding
Ho4 : There will he no statistically significant effect of 24 eeks supplementation
with 200 ~g chromium per day~ as chromium chloride, on percent specific insulin binding
among glucose intolerant men.
Repeated measures analysis of variance did not sho a significant group by time
interaction for mean percent specific insulin binding therefore the researcher fails to
reject the null hypothesis. Bhathena et al. reported a percent specific insulin binding per
100 Jlg protein of 2.51 % for healthy individuals (Bhathena et aI., 1995). This alue is
similar to the percent specific insulin binding observed in the current study.
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CHAPTER V
SUMMARY~ CONCLUSIONS, AND RECOMMENDATIONS
Summary
This study investigated the effects of 24 weeks of 200 Jlg chromium
supplementation per day as chromium chloride on glucose intolerance in men. Twenty
men with glucose intolerance were matched to one of two groups. The groups were then
randomly assigned to receive either a chromium supplement, which contained 200 fJ.g
chromium as chromium chloride. or a lactose placebo for 24 weeks. Measurements on
three-hour serum glucose curves, three-hour serum insulin curves, percent glycosylated
hemoglobin concentrations, and percent specific insulin binding were conducted at
baseline and after 24 weeks supplementation. Three participants were excluded from final
data analysis due to non-compliance or failure to arrive at the final data collection. As a
result, 9 participants were in the chromium group, and 8 participants were in the placebo
group for final data analysis. Repeated measures analysis of variance showed a
significant group by time interaction in three-hour serum glucose concentrations at 30
and 60 minutes following a 75 g oral glucose challenge. Repeated measures analysis of
variance did not show a significant group by time interaction for three-hour serum insulin
concentrations, glycosylated hemoglobin concentrations, or percent specific insulin
binding after 24 weeks supplementation.
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Conclusions
In conclusion, the results of this stud indicate a trend for chromium having a
beneficial effect on glucose and insulin concentrations in men ith glucose intolerance.
However with the new AI for chromium being so much 10 er than the previous
ESADDI., further research is needed investigating effects of chromium supplementation
at lower levels of chromium intake.
Recommendations
A crossover experimental design may have been beneficial due to the small
sample size. A crossover design would have increased the number of participants
receiving the chromium supplements.
Meeting individually with the participants during the study might have helped to
ensure compliance. Simply delivering the supplements to the participants personally each
month may not have been enough contact to encourage full compliance.
Having a trained researcher such as a health care provider or a dietetic intern
complete the food frequency questionnaire one-on-one with each participant, instead of
the participants completing the questionnaire on their own may improve food frequency
records.
Fructosamine, which is a test for glucose control might be helpful to run in this
type of research. Fructoseamine is a longer term-test indicator of glucose control than
serum glucose concentration, but it is a shorter-term indicator than glycosylated
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herTIoglobin. This test might better reflect the impact of chromium supplementation in
studies done for a length of time similar to that in the current stud .
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APPROVAL FORMS FOR INSTITUTIONAL REVIEW BOARD FOR HUMAN
PARTICIPANT RESEARCH
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DATE: 02-09-99
OKLAHOMA STATE UNIVERSITY
INSTITUTIONAL REVIEW BOARD
IRB #: HE-99-058
Proposal Title: EFFECTS AND INTERACTIONS OF CHROMIUM AND
COPPER SUPPLEMENTATION ON INDICATORS OF DIABETES IN
PREDIABETIC MEN WITH HYPERINSULINEMIA
Principal Investigator(s): Janice R. Hennann
Reviewed and Processed as: Expedited
Approval Status Recommended by Reviewer(s): Approved
Signature: Date: February 10, 1999
Carol Olson, Director ofUniversity Research Compliance
Approvals are valid for one calendar year~ aftt;r which lime a request for continuation must be submitted.
Any modifiC3tion to the research project approved by the IRE must be submitted for approval. Approved
projects are subject 10 monitoring by the IRB. Expedited and exempt projects may be reViewed by the full
Institutional Review Board.
OKLAHOMA STATE UN1VERSITY
)NSTJTUT10NAL RE\'JEW BOARD
Date: D~mber 9.1999 IRB #: HE·99·058
Proposal Title:
Principal
Investigator(s):
Reviewed and
Processed as:
"EFFECTS AND fNTERACTlONS OF CHR01vfiUM AND COPPER
SQPPLEMENTAT10N ON TND1CATORS OF D1ABETES TN PREDIABETIC
MEN WlTIJ HYPERINSVLJNEMJA"
Janice Hermann
Continuation
Approval Status Recommended by Reviewer(s) Approved
Carol Olson, Director ofUniversity Research Compliance
December 9 1999
Date
Approvals are valid for one calendar year, after which time a request for continuation must be submitted. Any
modification to the research project approved by the )RB must be submitted for approval with the advisor's signature.
The IRB office MUST be notified in writinE \\-hen a PIOJecllS complete. Approved projects are subject to monitoring
by the JRB. Expedited and exempt projects may be revIewed by the fuJllnstitutionaJ Review Board.
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INSTITUTIONAL REVJEW BOARD'
Date: Jan~ary 31, 2000 IRB #: HE-99-0S8
Proposal Title:
Principal
Investigator(s):
Reviewed and
Processed as:
"EFFECTS AND INTERACTIONS OF CHROMIUM AND COPPER
SuPPLEMENTAnON ON lND1CATORS OF DIABETES IN PREDIABETIC
MEN WITH HYPERINSULINEMIA II
J&nice H ennann
Modification
Approval Status Recommended by Reviewer(s): Approved
Signature:
Carol Olson, Director ofUniversity Research Complianct
January 31 2000
Date
Approvals are valid foc -ODe calendar year, after which time I request for continuation must be submitted. Any
modificatioo to the reseaicb project approved by the IRB must be submitted f(X' approval "With the advisors signature.
The IRB office :MUST be notified in writin~ wbco a project is romplcte. Approved projects are subject to~
by the IRB. Expedited and exempt projects may~ reviewed by the fulllnstitutional Review Board.
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RECRUITMENT .A.NNOUNCEMENTS
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ARE YOU AT RISK FOR
DEVELOPING DIABETES?
Male .Paryicipants Wanted Who Are At Risk For Diabetes
Did you know that low intake of certain minerals may increase your risk
of developing diabetes?
Would you like to know if an adequate mineral intake lowers your risk of
developing diabetes?
You may be at risk of developing diabetes if you have one or more of the
following:
• Over 40 years of age
• Overweight
• Family history of diabetes
Volunteers who meet the study criteria will receive $300 for
completing the study.
For further infonnation about the men's diabetes study please contact:
Janice R Hermann, PhD, RDILD
Department ofNutritional Sciences
Oklahoma State University
Stillwater., Oklahoma 74078
(405) XXX-XXX
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l\PPENDIX C
NEWSPAPER RECRUITMENT ADD
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Men at risk for diabetes wanted for OSU nutrition study. Factors increasing risk of
diabetes include family history of diabetes, overweight, over 40 years of age. 'Men
meeting the study criteria will receive $300 for completing the study. Call XXX-
xxx.
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APPENDIX D
INFORMED CONSENT FORM TO PARTICIPATE IN SCREENING
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INFO~fED CONSENT FOR MEN'S DIABETES STUDY SCREENING
Effect of Chromium Supplementation on Indicators of Diabetes in Men at Risk for Diabetes
"I, . ' hereby volunteer to participate in
the screening for the above titled study and authorize or direct Janice R. Hennann, Ph.D.,
R.D./L.D., or associates of her choosing, to perform the following treatment or procedure."
I understand that:
(I) this is a screening for fasting and 2 hour glucose as criteria for participating in the above
titled study on indicators of diabetes in men at risk for diabetes;
(2) I will have my finger pricked with a finger-lancing device by trained personnel to obtain
a drop of blood from which my fasting whole blood glucose will be measured using a
HemoCue instrument.
(3) If my fasting whole blood glucose measured with the HemoCue is below 126 mg/dL, a
licensed phlebotomist will draw a fasting blood sample of 6-ml by venipuncture. After
which I will consume a glucose drink containing 75-g glucose. I will have a 6-mI blood
sample dra\Vll by venipuncture by a licensed phlebotomist 120 minutes after consuming
the glucose drink.
(4) I may have slight discomfort and/or bruising from the venipuncture;
(5) after the two-hour blood sample I will receive a light meal for nutritional support;
(6) my blood will only be used for the study protocol, and any remaining blood will be
discarded and no further tests will be run~
(7) I will complete a Health Questionnaire concerning health conditions, medication use,
vitamin and mineral supplement use and exercise practices;
(8) I will have my height and weight measured~
(9) all my records are confidential and my name will not be associated with any reports;
(10) I will receive a [onn with my personal fasting and two-hour serum glucose
concentrations with accepted ranges for each laboratory value. There will be a statement
at the bottom of the form indicating that I should see a physician if my personal
laboratory results are not in the accepted ranges.
(II) my participation in the screening is voluntary, that there is no .penalty for refusal to
participate~
(12) I will be notified by the project director if I meet the criteria to participate in the study;
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(13) meeting the criteria for the study does not mean I am committed to participate in the
study, my participation in the study is voluntary, that there is no penalty for refusal to
participate, and that I am free to \vithdraw my consent and participation in this project at
any time without pen~lty after notifying the project director;
(14) this research is beneficial to the public in that the risk of diabetes increases with age and
low mineral intake.
(15) I may contact Dr Janice Hennann at (405) 269-1002 should I wish further information. I
may also contact Sharon Bacher, IRE Executive Secretary, 203 Whitehurst, Oklahoma
State University, Stillwater, OK 74078; telephone (405) 744-6244.
I have read and fully understand the consent fonn. I sign it freely and voluntarily. A copy has
been given to me.
(a.m./p.m.)Time
----- ~ ~~..;..L.
Date _
Signed _
Signature of Subject
I certify that I have persoIlally explained all elements of this fonn to the subject before
requesting the subject to sign it.
Signed _
(project director or her authorized representative)
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HEALTH QUESTIONNAIRE
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HEALTH QUESTIONNAIRE
I Screening Code _
. Date of Birth _
Do you have or have you' ever been told you had any of the following conditions?
onditions NO YES Specify
iabetes
roily history of
lbetes
gh blood pressure
gh triglycerides
art disease
ler health
nments
Do you currently take any medications on a regular basis? No Yes _
Specify all medications taken on a regular basis:
ne How often __ per day Or __ per week
ne How often __ per day Or__ per week
ne Ho-w' often __ per day Or __ per week
rle How often __ per day Or __ per week
Ie How often __ per day Or __ per week
~o you exercise on a regular basis? No Yes _
[ow many times a week do you regularly exercise? _
[ow many minutes would you estimate you regularly exercise in a week? _
BE COMPLETED BY RESEARCH STAFF
ing Glucose mg/dL Two-Hour Glucose mg/dL
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APPENDIX F
GLUCOSE TOLERANCE BEVERAGE
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Glucose Tolerance Beverage
Orange Flavored
Carbonated. CaHeine Free
For prescription use only
Catalog No. 401207 100 9 Dextrose, 10 fl. oz. (296 mL)
ManOfa~mfeo bY.
CASCcrNERl Diagnostics Baltimore. MD 21224 '·888-831·9800 Rev 9198_8_
4 fa CASCO·~~
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CAUTION: Federal law (U S A. ) prohibits dispensing withoLJI a pIP.sCrlptlOn
Active Ingredient: 100 g o\ucose per II 02 (296 mL) Contains CClrDonatr.d water. de);1rose
(d-glucose; source corn). nalural flavoring. Cltnc aCId. sodium benzoate. FO&C Yellow No 6
(Sunset Yellow) as ? color additive.
Indications and Usage: Trutol Y 100 is indicated for the det(;Cllon of gll~cose Intolerance In ttle
evaluation 01 ~estatlonal diabetes mellitus For oral consumption only
Precautions: Preqnant or nurSln~ women and persons having diabetes lake Tr\Jlol'" 100 only
under the dlreclton of a physician
Adverse Reactions: The most common adverse reactIons to Trutol" 100 are nausea. vomiting.
abdomH~1 bloating and/or head~che
Oosage and Administration: The recommended usual do~age IS 100 02 (1 OOg de;ttrose) lor
pregnan~ women InslrUCi1 the patient to remain QUiet. refrain from smoking and !rom drlnklnQ
beverages corrtalnJnQ caHeine just before and during the test Start liming when the pa1ient
begins to drink Trutol'"' 100 (drink in about 5 min). Obtain blood sample 1 hr later. To enhance
palalabi!lty. chill before serving. Protect from light. Do not freeze Discard unused contents.
Reference: For further details on the test and its interpretation. see: Summary and
Recommendations of the Second International Workshop-Conference on Gestational
Diabetes Mellitus. 34 (2) DIABETES 123. June 1985.
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Men's Diabetes Stud)': Effect of Chromium Supplementation
on Indicators of Diabetes in Men at Risk for Diabetes
"I,. . . ' hereby volunteer to participate in the above titled study and
authonze or dIrect JanlGe R. Hermann, Ph.D., R.D./L.D., or associates or assistants of her
choosing, to perfonn the tolIo\ving treatment or procedure."
I understand that:
(1) ~e purpose of the study is the measure the effect of chromium supplementation on
indIcators of diabetes in prediabetic men with elevated insulin;
(2) I will receive one month's of supplements containing ONE of the following:
(a) a placebo
(b) 200 ug chromium
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(1 1)
(12)
(13 )
( 14)
I will take one supplement a day with a meal for 24 weeks;
I will not take any other vitamin/mineral supplements or herbal/dietary supplements that
contain chromium other than those that are part of this study;
I will return each month to receive the next month's supplements.
I will participate in a fasting blood collection and j-hour glucose toierance test at the
begiIUling of the study, after 12 weeks supplementation and after 24 weeks
supplementation. A licensed phlebotomist will draw a fasting blood sample of20 ml by
venipuncture. After which I will consume a glucose drink containing 75-g glucose. I
will have a 6 ml blood sample drawn by venipuncture by a licensed phlebotomist 30, 60,
120, and 180 minutes after consuming the glucose drink.
I may have slight discomfort and/or bruising from the venipuncture.
after the 3-hour glucose tolerance test I will receive a light lunch for nutritional support.
my blood will only be used for the study protocol, and any remaining blood tissue wi II be
discarded and no further tests wi I) be run.
routine measurements of my body weight will be taken at the beginning of the study,
after 12 weeks supplementation and after 24 weeks supplementation;
I will complete a Health Questionnaire concerning health conditions, medication use,
vitamin and mineral supplement use and exercise practices at the begirming of the study,
and a Follow-up Health Questionnaire after 12 weeks supplementation and after 24
weeks supplementation~
I will complete a I-week food frequency questionnaire at the beginning of the study,
after 12 weeks supplementation, and after 24 weeks supplementation~
as a reward for participation and as an incentive to complete the study, I will receive
$150 after completing each of the three data collections for a total of $4 50~ $150 after the
data collection at the beginning of the study, $150 after the data collection after 12 weeks
supplementation, and $150 after the data collection after 24 weeks supplementation.
all my records are confidential and that my name \r,,:ill not be associated y..l ith any reports
or data records at the end of the study~
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(15) I will receive a form with my personal laboratory results with accepted ranges for each
laboratory value. There Vlill be a statement at the bottom of the form indicating that I
should see a physician if my personal laboratory results are not in the accepted ranges.
(16) my participation is voluntary, that there is no penalty for refusal to participate, and that I
am free to withdraw my consent and participation in this project at any time without
penalty after notifying the project director;
(17) I will withdraw from the project if I need to begin taking medication for diabetes during
this study;
(18) this research is beneficial to the public in that the risk diabetes increasing with age and
low mineral intake.
(19) I may contact Dr Janice Hennann at (405) 269-1002 should I wish further infonnation.
may also contact Sharon Bacher, IRE Executive Secretary, 203 Whitehurst, Oklahoma
State University, Stillwater, OK 74078; telephone (405) 744-6244 ..
I have read and fully understand the consent fonn. I sign it freely and voluntarily. A copy has
been given to me.
Date _ Time ----a...(a_.......m......I-'"D....;·m---...-.)
Signed, ~ ----------
Signature of Subject
I certify that I have personally explained all elements of this form to the subject before
requesting the subject to sign it.
Signed .
(project director or her authorized representatl ve)
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FOOD FREQUENCY QUESTIONNAIRE
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Code Number
----
Men's Diabetes Study
Seven Day Food Frequency Questionnaire
This questionnaire asks you about your consumption of foods and beverages over
the past week. The UHo~" Often" columns are for day. week, or rarely/never. \\/e
want you to think back over the past week and te)) us how many times (per day or
per week) you consumed each item. A medium serving is in parentheses.
EXAMPLES:
Ate 1/2 grapefruit about t\vice last week.
Ate] large hamburger four times last week.
Drank 2 cups of whole milk each day.
Type of Food I 1-10\\' Often Size
(Medium Serving) I Day Week Rarely/ S M L
I Never
Grapefruit (1/2) 2 X
Hamburger, regular (I £atty, 3 oz) J 4 X
Whole milk (1 cup, 8oz) J 2 X
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Type of Food 1 Ho" Often ISize
(Medium Serving) I Day I eek Rarely/ Is 1M LI I Never I ;
DAIRY FOODS I I~ I
Whole milk (I cup, 8 at) I I
20/0 milk (1 cup, 8 oz) ----------j---------------,--1--- ;----
1% milk (1 cup~ 8 oz) :I
Skim milk (] cup, 8 oz) : I I
- .
i
Rice milk (] cup, 8 oz) ! I I ! II
Soy milk (I cup, 8 oz) !I
Milk Shake (] 6 oz) I ; i
Pudding (] /2 cup) I ! ;
Cream, whipped (] Tbsp) !
Sour cream (J Tbsp) ! I I II
Coffee cream (I Tbsp) ! I !i
Ice cream (~ cup) I
Low fat ice cream (Y2 cup) I I~
Frozen yogurt (~ cup) II
Yogurt (1 cup) i II
Low fat yogurt (1 cup)
Cottage cheese (Y2 cup) - ----- - ----- -------l--- ---I----t
Cream cheese (1 oz) i : I: !
Low fat cream cheese (1 oz) i
Other cheese (] slice or 1 oz)
Low fat cheese (1 slice or 1 oz) II I i
Margarine (1 tsp) i
Butter (1 tsp)
Reduced fat margarine (1 tsp) i
! !i
I I I I
i i I
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Type of Food Ho\\' Often Size
(Medium Serving) Day Week Rarely/ S M L
Never
FRUITS, FRUIT JUJCES
Raisins (I oz or 1 sm box)
Grapes (20) I
Prunes (~ cup) ~ I
Bananas !
Cantaloupe (Y4 melon)
Watermelon (1 slice)
Apples, applesauce or pears
(1 fresh, 12 cup)
Apple juice (~ cup) I
Oranges I
Orange juice (~ cup) 1
Grapefruit (~ cup)
Grapefruit juice (~ cup)
Cranberry juice (Yl cup)
Other fruit juices (~ cup)
Strawberries-fresh, frozen, or canned
(~ cup)
Blueberries-fresh, frozen, or canned
(~ cup)
Peaches (1 fresh, ~ cup canned) i II
Apricots (1 fresh, ~ cup canned)
Plums (1 fresh, ~ cup canned)
Honeydew melon (~ melon)
Kiwi (I medium)
Fruit Cocktail (~ cup)
Mango (~ cup, or ~ small)
Raspberries (~ cup) !
Blackberries (~ cup) !
Dried fruit (1/4 cup) II
Pears (1 medium) I
I
Pineapple chunks (lh cup) !
Lemon juice (1/4 cup)
Lime juice (1/4 cup)
: ,
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Type of Food I Ho,,' Often Size
(Medium Serving) f-Day Week Rarely/ S' M L
I Never
VEGETABLES, lIVEGETABLE JUJCE ,I
Tomatoes (] ) ~
Tomato juice (Y2 cup) ~ - I
Tomato sauce (Y2 cup) 1
Spaghetti sauce (~ cup) II
Red chili sauce, taco sauce, or salsa i(1 Tbsp) I
Tofu or soybeans (3-4 oz) I
String beans, Qreen beans (~ cup) i !
Broccoli (Y2 cup) I
Cabbage (112 cup) I
Cole slaw (Y2 cup) I~
Cauliflower (Y2 cup) I
Brussels sprouts (Y2 cup) II
Carrots, raw (1;'2 carrot or 2-4 sticks)
Carrots, cooked ('l2 cup)
Com (1 ear or ~ cup frozen or canned)
Peas (~ cup fresh, frozen or canned)
Lima beans (~ cup frozen, or canned)
Mixed vegetables (Y2 cup) I
Beans or lentils, baked or dried (Y2 cup)
Summer or yellow squash ('l2cup)
Winter squash (Yi cup)
Zucchini (1h cup)
Yam or sweet potato (Y2 cup)
Spinach, (cooked.~cup, raw 1 cup) i
lceberg lettuce, romaine or leaf (] cup)
Celery (4'~ stick)
Beets (~ cup) I
Alfalfa sprouts (Y2 cup) ! ,
Kale, mustard~ or chard greens ()/2 cup) !
Vegetable, vegetable beef, minestrone !
or tomato soup (1 cup) I
Okra ()/2 cup)
Cucumber slices (Y2 cup) I :
i
!
: i
74
Type of Food I HO~1 Often Size
(Medium Serving) I Day Week Rarely/ S M L
Never
VEGETABLES, I
VEGETA-BLE JUICE (Coot.) ~
Mushrooms (~ cup) !
Collard greens ('is cup)"- _ :i
Turnip greens (Y2 cup)
Onion (~ cup) !
Pickles (Y2 cup) :
Sweet peppers (Y2 cup)
Asparagus (~ cup)
Jalapeno peppers (1/4 cup)
Potato salad ('l2 cup) !i
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Type of Food f Ho,,' Often Size
(Medium Serving) I Da~· Week Rarely/ S M L
I Never
EGGS, MEAT, ECT.
EEgs (2)
Chicken or turkey, ro~sted or broiled I
with skin (3-4 oz) .. Ji
Chicken or turkey, roasted or broiled II
skinless (3-4 oz) I
Chicken, fried with skin (3-4 oz)
Bacon (2 slices) ;
Hot dogs (2) i I
Low fat hot dogs (2)
I
Sausage (2 patties or 2 Jinks) :
Bologna (I slice) !
Other processed luncheon meat (] slice) : I
Liver, chicken or beef(3-4 oz) I !
Hamburger, regular (1 patty, 3-4 oz) i
Hamburger, lean (1 patty, 3-4 oz) ~
~eat loaf(3-4 oz) !
Pork, chops, roasts (3-4 oz) 1
Lamb (3-4 oz) !
Beef, roast, steak (3-4 oz) !
Beef stew with vegetables (1 cup) !
Ham (3-4 oz) j
Tuna (3-4 oz) I
Tuna salad (Y2 cup) I
Fish, baked or broiled (3-4 oz) ;
Fish, fried or fish sandwich (3-4 OZ) I
Shrimp, Lobster, Scallops
Pizza (2 slices) ;
Mixed d-ishes with cheese (1 cup) I
Lasagna or meat pasta dishes (I CUP) !
Pot pie (1 each) I ~Egg beaters (Y2 cup) I
Pork ribs (3 ribs) !
Deli meats (3 oz) I
Ground turkey (3 oz) 1
Chicken salad (~ cup) I iI
Chili (1 cup) i i
f----- !
!
I
.- ..-
. - .
_.-. -
!
-.- . ~ --
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Type of Food How Often Size
(Medium Serving) Day Week Rarely/ S M L
Never
BREADS, CEREALS, STARCHES
Cold breakfast cereal (1 cup)
Cold breakfast cereal--fDrtified (] cup)
Cooked oatmeal (1 cup)
Other cooked breakfast cereal (1 cup)
White bread (1 slice)
Pita bread (1 piece)-
Dark bread (1 slice)
English muffin (I)
Bagel (1)
Dinner roll (1)
Hamburger or hotdog bun (1)
Muffin (1)
Biscuit (I )
Com bread, com muffin (1)
Brown rice (lcup)
White rice (lcup)
Spaghetti noodles (1 cup)
Macaroni noodles (1 cup)
Other pasta noodles (1 cup)
Bulgar, kasha, couscous (1 cup)
Pancakes or waffles (2)
Potatoes, french fries or fried (Y2 cup)
Potatoes, baked or boiled (1 )
Mashed potatoes (1 cup)
Potato chips or corn chips
(small bag or 1 oz)
Saltine crackers (5)
Saltine crackers, low sodium (5)
Saltine crackers, fat free (5)
Other crackers (5)
Other crackers, Jow fat (5)
Tortilla (I medium)
Graham cracker (3 medium)
Pretzels (15 small)
Trail mix (1 cup)
1 ____ -
- --
J __L-
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Type of Food Ho\\' Often Size
(Medium Serving) Day Week Rarely/ S M L
Never
BEVERAGES
Regular soft drink (1 )
Diet soft drink (1)
Caffeine free soft drinkj) )
Caffeine free, Diet soft drink (I)
Lemonade or other non-carbonated
drink (1 glass, bottle, or can)
Coffee (1 cup)
Decaffeinated coffee (1 cup)
Tea (1 cup) !
Herbal tea (1 cup)
Beer (1 glass, bottle: or can)
Red wine (4 oz glass)
Pink wine (4 oz glass)
White wine (4 oz Qlass)
Whiskey, gin, or other liquor
(1 drink or shot)
78
Type of Food Ho,,' Often Size
(Medium Serving) Da : Week Rarely/ S M L·
Never
SWEETS, BAKED GOODS, MISC. I
Sorbet (~ cup)
Granola bar (I small bar) ! i
Chocolate (1 small bar Of 1 oz)
Candy bar (I small bar)
Candy without chocolate (] oz)
Cookies, home baked (2)
Cookies, ready made (2)
Brownies (2)
Doughnuts (2) I
Cake, home baked (1 slice)
Cake, ready made (I slice)
Sweet roll, coffee cake, or other pastry
Iready made (1 serving)
Sweet roll, coffee cake, or other pastry
home baked (I serving)
Pie, homemade (1 slice)
Pie, ready made (I slice)
Jam, jelly, preserves, syrup, or Honey
(1 Tbsp) ,
Peanut butter (I Tbsp) Ii
Popcorn (1 cup) I
Popcorn, air popped (1 cup) II
Nuts (small packet or 1 oz) !
Bran, added to food (1 Tbsp) I
Wheat germ (I Tbsp) I
Chowder or cream soup (I cup) !
Oil and vinegar dressing (1 Tbsp)
Soy sauce (1 tsp) :
Mayonnaise or other creamy salad I
dressing (1 Tbsp)
Mustard, dry or prepared (1 tsp) I
Salt (1 shake) i
Pepper (1 shake) I
I
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